Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1719200

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what flexibility (a) NICE and (b) NHS England have to approve for use drugs that (i) are used in combination with other drugs, (ii) are used for various (A) conditions and (B) lines of treatment and (iii) provide significant benefits for some but not all patients; and what tools those organisations use to ensure the effectiveness of such appraisals.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	27051
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines, and significant licence extensions for existing medicines, should be routinely funded by the NHS. The NICE is able to recommend most new medicines for use by the NHS, including as a result of commercial agreements negotiated between NHS England and the company, in line with the commercial framework for new medicines.</p><p>The NICE develops its guidance in line with its published health technology evaluations manual, which sets out the circumstances in which its Appraisal Committees are able to apply flexibility in the evaluation of specific treatments. The NICE is, for example, able to apply a modifier in the evaluation of medicines for severe diseases that means that its committees are able to recommend medicines at a higher cost-effectiveness threshold than for less severe diseases. The NICE appraises combination therapies using the same methods that it uses for appraising single drug therapies.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 16:08:56 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1719284

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the adequacy of access to (a) Creon and (b) other drugs that contain pancreatic enzymes for patients after pancreatic surgery.
tabling member constituency	Broxbourne
tabling member printed	Sir Charles Walker
uin	26982
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10,000 gastro-resistant capsules; Creon 25,000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 15:24:29 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1493 label Biography information for Sir Charles Walker

1719292

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prince's Trust: Contracts
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Minister without Portfolio's article of 12 May 2024 in The Sunday Telegraph, when her Department is expected to terminate its contract with the Prince's Trust, order reference C191156; and whether a notice period is required under the provisions of clause 10.2.2 of that contract.
tabling member constituency	Islington South and Finsbury
tabling member printed	Emily Thornberry
uin	26990
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Dissolution.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/05/2024 14:03:28 answering member 4044 label Biography information for Andrew Stephenson previous answer version 36822 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
tabling member	1536 label Biography information for Emily Thornberry

1719342

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	South Asia Bio Bank: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will have discussions with (a) the National Institute for Health Research and (b) other NHS funding streams on the potential merits of increasing the level of funding made available to the South Asian Biobank to help monitor (i) disease diagnoses and (ii) health outcomes from that project among people from South Asian backgrounds.
tabling member constituency	Walsall South
tabling member printed	Valerie Vaz
uin	27023
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The South Asian Biobank, originally funded by the Wellcome Trust, is an international research study designed to prevent the high risk of cardiovascular disease, diabetes, and cancer among South Asian people. The National Institute for Health and Care Research (NIHR) funds research via a range of programmes, with eligibility criteria to support applicants to decide where to apply. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. The NIHR has provided funding for research projects associated with the South Asian Biobank through open competition, and welcomes any future applications. In addition, the NIHR provides funding to NIHR research infrastructure through open competition. The NIHR Imperial Biomedical Research Centre and the Clinical Research Network have provided support for the South Asian Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 27025 question first answered 23/05/2024 07:42:45 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4076 label Biography information for Valerie Vaz

1719343

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	UK Biobank: Ethnic Groups
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) UK Biobank and (b) UK Biobank funders on the adequacy of the proportion of UK Biobank participants from BAME backgrounds.
tabling member constituency	Walsall South
tabling member printed	Valerie Vaz
uin	27024
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>The scientific and ethical impacts of cohort diversity on the generalisability of research findings is part of ongoing conversations on health data, including with UK Biobank. As a funder, the Government routinely engages in discussions about diversity with UK Biobank through the Medical Research Council and National Institute for Health and Care Research. The Department is committed to increasing participation of ethnic minority groups in health and social care research, and is working in partnership with diverse communities to ensure they have a stronger voice in shaping priorities for research, the design and delivery of research, inclusive recruitment into studies, and the mobilisation of evidence into practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/05/2024 13:29:24 answering member 4044 label Biography information for Andrew Stephenson previous answer version 36821 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
tabling member	4076 label Biography information for Valerie Vaz

1719345

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	South Asia Bio Bank: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of increasing the level of funding allocated to the South Asian Biobank.
tabling member constituency	Walsall South
tabling member printed	Valerie Vaz
uin	27025
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The South Asian Biobank, originally funded by the Wellcome Trust, is an international research study designed to prevent the high risk of cardiovascular disease, diabetes, and cancer among South Asian people. The National Institute for Health and Care Research (NIHR) funds research via a range of programmes, with eligibility criteria to support applicants to decide where to apply. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. The NIHR has provided funding for research projects associated with the South Asian Biobank through open competition, and welcomes any future applications. In addition, the NIHR provides funding to NIHR research infrastructure through open competition. The NIHR Imperial Biomedical Research Centre and the Clinical Research Network have provided support for the South Asian Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 27023 question first answered 23/05/2024 07:42:45 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4076 label Biography information for Valerie Vaz

1719358

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cryptosporidia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many cases of Cryptosporidiosis have been recorded (a) by each NHS trust, (b) by each integrated care board and (c) in total in each of the last ten years.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	27123
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>While this information is not held in the requested format, the following table shows the laboratory reported figures for cryptosporidiosis, and the reports of cryptosporidiosis per 100,000 people, in England and Wales, each year from 2008 to 2017:</p><table><tbody><tr><td><p>Year</p></td><td><p>Number of laboratory reports</p></td><td><p>per 100,000 population</p></td></tr><tr><td><p>2008</p></td><td><p>4,162</p></td><td><p>7.6</p></td></tr><tr><td><p>2009</p></td><td><p>4,831</p></td><td><p>8.7</p></td></tr><tr><td><p>2010</p></td><td><p>3,901</p></td><td><p>7.0</p></td></tr><tr><td><p>2011</p></td><td><p>2,990</p></td><td><p>5.3</p></td></tr><tr><td><p>2012</p></td><td><p>5,765</p></td><td><p>10.2</p></td></tr><tr><td><p>2013</p></td><td><p>3,520</p></td><td><p>6.2</p></td></tr><tr><td><p>2014</p></td><td><p>4,023</p></td><td><p>7.0</p></td></tr><tr><td><p>2015</p></td><td><p>5,222</p></td><td><p>9.0</p></td></tr><tr><td><p>2016</p></td><td><p>5,925</p></td><td><p>10.1</p></td></tr><tr><td><p>2017</p></td><td><p>4,292</p></td><td><p>7.3</p></td></tr></tbody></table><p><br> Source: data is taken from Public Health England’s report, Cryptosporidium data 2008 to 2017, available at the following link:<br> <a href="https://www.gov.uk/government/publications/cryptosporidium-national-laboratory-data/cryptosporidium-data-2008-to-2017" target="_blank">https://www.gov.uk/government/publications/cryptosporidium-national-laboratory-data/cryptosporidium-data-2008-to-2017</a><br> <br> Note: figures for England 2018 to 2023 are due to be published in Summer 2024.</p><p>In addition, the following table shows the regional distribution of the laboratory reports of cryptosporidium in England and Wales, in 2017:</p><table><tbody><tr><td><p>Country</p></td><td><p>Region</p></td><td><p>Number of laboratory reports</p></td><td><p>per 100,000 population</p></td></tr><tr><td><p>England</p></td><td><p>East Midlands</p></td><td><p>378</p></td><td><p>7.9</p></td></tr><tr><td><p>England</p></td><td><p>East of England</p></td><td><p>539</p></td><td><p>8.7</p></td></tr><tr><td><p>England</p></td><td><p>London</p></td><td><p>250</p></td><td><p>2.8</p></td></tr><tr><td><p>England</p></td><td><p>North East</p></td><td><p>275</p></td><td><p>10.4</p></td></tr><tr><td><p>England</p></td><td><p>North West</p></td><td><p>554</p></td><td><p>7.6</p></td></tr><tr><td><p>England</p></td><td><p>South East</p></td><td><p>582</p></td><td><p>6.4</p></td></tr><tr><td><p>England</p></td><td><p>South West</p></td><td><p>590</p></td><td><p>10.6</p></td></tr><tr><td><p>England</p></td><td><p>Yorkshire and The Humber</p></td><td><p>450</p></td><td><p>8.3</p></td></tr><tr><td><p>England</p></td><td><p>West Midlands</p></td><td><p>414</p></td><td><p>7.1</p></td></tr><tr><td><p>Wales</p></td><td><p>Wales</p></td><td><p>260</p></td><td><p>8.3</p></td></tr></tbody></table> answering member constituency Lewes answering member printed Maria Caulfield question first answered 23/05/2024 12:25:16 answering member 4492 label Biography information for Maria Caulfield
tabling member	4603 label Biography information for Preet Kaur Gill

1719042

registered interest
date	17/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemochromatosis: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of diagnosis rates for genetic haemochromatosis.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	26852
answer	answer is ministerial correction date of answer 22/05/2024 answer text <p>While data is not held centrally on diagnosis rates for genetic haemochromatosis, genomic testing for haemochromatosis is available through the NHS Genomic Medicines Service (GMS) for patients in England who show an unexplained iron overload, suggestive of genetic haemochromatosis. Any clinician who suspects haemochromatosis can order this testing via local genomic laboratory hubs.</p><p>Seven NHS GMS Alliances play an important role in supporting the strategic systematic embedding of genomic medicine in end-to-end clinical pathways and clinical specialities. They help to achieve equitable access to standardised end-to-end pathways of care, inclusive of genomic testing, clinical genetics, and genomic counselling services. The alliances also raise awareness among clinicians and the public of the genomic testing available through the National Health Service and drive this embedding across all providers within their geography, from primary and community care to secondary and tertiary care.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/05/2024 19:44:14 answering member 4044 label Biography information for Andrew Stephenson previous answer version 35987 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
tabling member	1409 label Biography information for Mr Gregory Campbell

1719049

registered interest
date	17/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Neurofibromatosis: Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of automatically notifying women with neurofibromatosis type 1 before their 40th birthday that they are eligible to attend breast cancer screening from the age of 40 years.
tabling member constituency	Blaydon
tabling member printed	Liz Twist
uin	26906
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>Currently women with neurofibromatosis type 1 (NF1) who are considered at moderate or high risk of breast cancer, can be referred through clinical professionals such as specialists in genetics or oncology for annual breast screening which is managed at a local level.</p><p>An assessment has not made of the potential merits of automatically notifying women with NF1 before they are 40 years old that they are eligible to attend breast cancer screening from the age of 40 years.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 08:07:57 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4618 label Biography information for Liz Twist

1719051

registered interest
date	17/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Neurofibromatosis: Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she has taken with NHS England to help raise awareness by (a) patients and (b) GPs of the increased risk of breast cancer in people with neurofibromatosis type 1.
tabling member constituency	Blaydon
tabling member printed	Liz Twist
uin	26907
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The Department works with NHS England to raise awareness of cancers, including for people with increased risk of cancer. In January 2024, NHS England relaunched the Help Us Help You cancer awareness campaign, designed to increase earlier diagnosis by encouraging people to come forward with suspected signs of cancers.</p><p>For individuals with neurofibromatosis type 1 (NF1), who are at increased risk of breast cancer, the National Health Service in England recommends breast screening from the age of 40 years old. It is important that awareness of this is widespread among patients and general practices (GPs). Treatment for NF1 involves regular monitoring, and if a patient develops complex problems, their GP can usually refer them to one of two specialist NHS centres, so that a treatment plan can be drawn up. These centres are at Guy’s and St Thomas’ in London, and at Manchester University Hospital.</p><p>We expect clinicians to keep themselves appraised of developments within conditions, and to refer to the National Institute for Clinical Excellence guidance as part of their clinical decision-making process.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 08:05:03 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4618 label Biography information for Liz Twist